Overview

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to characterize the safety and tolerability of GS-3583 as monotherapy, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of GS-3583 as monotherapy in participants with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Gilead Sciences